2024-515681-14-00招募中2 期
Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 25
- 试验地点
- 27
- 主要终点
- The activity of TEMIRI will be measured as the rate of patients with post-treatment seroreversion and disease-free at 2 years
研究概览
简要总结
To assess the activity in terms of seroreversion of temozolomide and irinotecan (TEMIRI) consolidation regimen administered to patients with high-risk stage II (pT4) or III microsatellite stable, MGMT silenced CRC and positive post-adjuvant ctDNA after standard oxaliplatin-based adjuvant chemotherapy.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Have provided written informed consent prior to any study specific procedures
- •Adequate organ function
- •Carcinoembryonic antigen (CEA) level = 10 ng/ml
- •No evidence of metastatic disease by chest and abdomen computed tomography (CT) scan
- •Male subjects with female partners of childbearing potential must be willing to use adequate contraception as approved by the investigator (barrier contraceptive measure or oral contraception)
- •Women of childbearing potential must have a negative blood pregnancy test at the baseline visit. For this trial, women of childbearing potential are defined as all women after puberty, unless they are postmenopausal for at least 12 months, are surgically sterile, or are sexually inactive.
- •Age = 18 years
- •Histologically confirmed diagnosis of stage III or T4N0 stage II colon cancer (located 12 cm from the anal verge by endoscopy and above the peritoneal reflection at surgery) or histologically confirmed diagnosis of locally-advanced resectable rectal cancer (proximal margin located at < 12 cm from the anal verge)
- •Completion of radical surgery for patients with colon cancer and preoperative chemoradiotherapy and radical surgery for patients with rectal cancer.
- •Completion of at least 3 months of oxaliplatin-based (CAPOX or FOLFOX) adjuvant chemotherapy (or candidate to oxaliplatin-based adjuvant chemotherapy if post-surgery pre-screening).
- •Absent MGMT expression by IHC, MGMT promoter methylation by pyrosequencing (> 5%) and MSS by standard assessment
- •Presence of ctDNA in the liquid biopsies collected at 2-6 weeks after the last dose of standard adjuvant chemotherapy
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •Completion of adjuvant chemotherapy for a duration of at least three months
排除标准
- •History of another neoplastic disease, unless in remission for = 5 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded
- •Known presence of one of the following UGT1A1 1(TA)6/UGT1A1 36(TA)5; UGT1A1 28(TA)7/UGT1A1 37(TA)8 (homozygous genotype)
- •Microscopic or macroscopic evidence of residual tumor (R1 or R2 resections). Patients should never have had any evidence of metastatic disease (including presence of tumor cells in the peritoneal lavage)
- •Inability to swallow pills
- •Active infection requiring intravenous antibiotics at the start of study treatment
- •Evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results
- •Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
- •Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Sexually active males and females (of childbearing potential) unwilling to practice contraception (barrier contraceptive measure or oral contraception) during the study and until 6 months after the last trial treatment
- •Clinically significant (i.e. active) cardiovascular disease, for example cerebrovascular accidents = 6 months prior to start of study treatment, myocardial infarction = 6 months prior to study enrolment, unstable angina, New York Heart Association (NYHA) Functional Classification Grade II or greater congestive heart failure, or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment
- •Previous treatment with temozolomide or irinotecan for any indication
结局指标
主要结局
The activity of TEMIRI will be measured as the rate of patients with post-treatment seroreversion and disease-free at 2 years
The activity of TEMIRI will be measured as the rate of patients with post-treatment seroreversion and disease-free at 2 years
次要结局
- Disease-free survival (DFS) of patients treated with TEMIRI as post-adjuvant regimen, defined as the time from enrolment to the first documentation of objective disease relapse determined by investigator assessment or death due to any cause, whichever occurs first
- Overaal survival (OS), defined as the time from enrolment to the date of death due to any cause. For patients alive at the time of analysis, the OS time will be censored on the last date the patients were known to be alive
- Safety that will be assessed by monitoring the frequency, duration, and severity of AEs through physical examinations, clinical laboratory blood and urine sample evaluations.
- The analysis of Patient Reported Outcomes (PROs) endpoints (assessed using the EORTC QLQ-C30, the EORTC QLQ-CR29 and the EuroQol EQ-5D questionnaires) will be performed according to the EORTC Scoring and Reference Values Manual. All scores and subscales will be assessed through descriptive summary statistics
- To develop a gene expression signature associated with temozolomide resistance/sensitivity by profiling tumor tissue blocks obtained prior to any treatment
- To assess the accuracy of liquid biopsies collected during follow-up to predict recurrence
研究者
Filippo Pietrantonio
Scientific
Fondazione IRCCS Istituto Nazionale Dei Tumori
研究点 (27)
Loading locations...
相似试验
尚未招募
1 期
A Phase 1 study of Temozolomide, Irinotecan, and O6BG (O6-Benzylguanine) for Children with Recurrent or Resistant NeuroblastomaACTRN12614000552684The Sydney Children's Hospitals Network24
已完成
2 期
Multicombination Therapy of Temozolomide, Vincristine, and Interferon-beta with Radiotherapy for Malignant GliomaJPRN-UMIN000040599Department of Neurosurgery, Hirosaki University School of Medicine50
进行中（未招募）
不适用
A Phase II study of Temozolomide (Temodal) Given Continously 100mg/m2 for 21 Days in 28 Day cycles in Patients with Metastatic Melanoma.Metastatic melanomaEUCTR2004-002925-39-SEKliniken för onkologi, Karolinska Universitetssjukhuset, Solna35
进行中（未招募）
1 期
A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter. - P04273Advanced Aerodigestive Tract Cancers (Colorectal Cancer (CRC), Non Small Cell Lung Cancer (NSCLC), Head & Neck (H & N), Esophageal Cancer).MedDRA version: 9.1 Level: LLT Classification code 10028980 Term: NeoplasmEUCTR2006-003169-15-ITSCHERING-PLOUGH160
进行中（未招募）
1 期
A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) PromoterAdvanced Aerodigestive Tract Cancers (Colorectal Cancer (CRC), Non Small Cell Lung Cancer (NSCLC), Head & Neck (H & N), Esophageal Cancer)MedDRA version: 8.1 Level: LLT Classification code 10028980 Term: NeoplasmEUCTR2006-003169-15-GRSchering-Plough Research Institute160